RALEIGH, N.C., May 18 /PRNewswire/ -- Encelle, Inc. has successfully completed a second human clinical trial for E-Matrix(tm) treatment of diabetic foot ulcers. This controlled, randomized fifty-six patient feasibility study provides the data necessary to design the next pre-market (pivotal) clinical trial, and preliminary safety and efficacy results.
Dr. Jason Hanft (South Miami, Fla.) the top enroller in the study said, "This novel approach to healing diabetic foot ulcerations demonstrated the potential to improve healing rates with excellent safety. A pivotal trial is necessary to fully explore this potential for an interesting new treatment for a difficult disease state."
Abstracts of the results have been accepted for platform presentations at two national wound healing meetings. Dr. Hanft presented the initial clinical trial results at the Society for Advanced Wound Care annual meeting in San Diego, Calif. in April. On May 20th, Dr. William A. Marston (UNC, Chapel Hill, N.C.) will provide additional results at the annual Wound Healing Society meeting in Chicago, Ill.
About Encelle, Inc.
Encelle, Inc. ( http://www.encelle.com/ ) has developed and patented products with broad therapeutic applications, including advanced wound repair, hard and soft tissue repair for orthopedics, and cosmesis. The company is headquartered in Raleigh, N.C., with research and pilot production facilities in Greenville, N.C.
Jim Woodward, CEO
CONTACT: Jim Woodward, CEO of Encelle, Inc., +1-919-877-8101